{"pmid":32300868,"title":"Balneotherapy and human immune function in the era of COVID-19.","text":["Balneotherapy and human immune function in the era of COVID-19.","Int J Biometeorol","Masiero, Stefano","Maccarone, Maria Chiara","Magro, Giacomo","32300868"],"journal":"Int J Biometeorol","authors":["Masiero, Stefano","Maccarone, Maria Chiara","Magro, Giacomo"],"date":"2020-04-18T11:00:00Z","year":2020,"_id":"32300868","week":"202016|Apr 13 - Apr 19","doi":"10.1007/s00484-020-01914-z","source":"PubMed","topics":["Treatment"],"weight":1,"_version_":1664357978587791360,"score":8.233237,"similar":[{"pmid":32157732,"title":"Harnessing the immune system via FcgammaR function in immune therapy: A pathway to next-gen mAbs.","text":["Harnessing the immune system via FcgammaR function in immune therapy: A pathway to next-gen mAbs.","The human FcgammaRs interact with antigen-complexed IgG ligands to both activate and modulate a powerful network of inflammatory host-protective effector functions that are key to the normal physiology of immune resistance to pathogens. More than 100 therapeutic monoclonal antibodies (mAbs) are approved or in late stage clinical trials, many of which harness the potent FcgammaR-mediated effector systems to varying degrees. This is most evident for antibodies targeting cancer cells inducing antibody-dependent killing or phagocytosis but is also true to some degree for the mAbs that neutralise or remove small macromolecules such as cytokines or other immunoglobulins. The use of mAb therapeutics has also revealed a \"scaffolding\" role for FcgammaR which, in different contexts, may either underpin the therapeutic mAb action such as immune agonism or may trigger catastrophic adverse effects. The still unmet therapeutic need in many cancers, inflammatory diseases or emerging infections such as SARS-CoV-2, requires increased effort on the development of improved and novel mAbs. A more mature appreciation of the immunobiology of individual FcgammaR function and the complexity of the relationships between FcgammaRs and antibodies is fuelling efforts to develop more potent \"next-gen\" therapeutic antibodies. Such development strategies now include focused glycan or protein engineering of the Fc to increase affinity and/or tailor specificity for selective engagement of individual activating FcgammaRs or the inhibitory FcgammaRIIb or alternatively, for the ablation of FcgammaR interaction altogether. This review touches on recent aspects FcgammaR and IgG immunobiology and its relationship to the present and future actions of therapeutic mAbs.","Immunol Cell Biol","Chenoweth, Alicia M","Wines, Bruce D","Anania, Jessica C","Mark Hogarth, P","32157732"],"abstract":["The human FcgammaRs interact with antigen-complexed IgG ligands to both activate and modulate a powerful network of inflammatory host-protective effector functions that are key to the normal physiology of immune resistance to pathogens. More than 100 therapeutic monoclonal antibodies (mAbs) are approved or in late stage clinical trials, many of which harness the potent FcgammaR-mediated effector systems to varying degrees. This is most evident for antibodies targeting cancer cells inducing antibody-dependent killing or phagocytosis but is also true to some degree for the mAbs that neutralise or remove small macromolecules such as cytokines or other immunoglobulins. The use of mAb therapeutics has also revealed a \"scaffolding\" role for FcgammaR which, in different contexts, may either underpin the therapeutic mAb action such as immune agonism or may trigger catastrophic adverse effects. The still unmet therapeutic need in many cancers, inflammatory diseases or emerging infections such as SARS-CoV-2, requires increased effort on the development of improved and novel mAbs. A more mature appreciation of the immunobiology of individual FcgammaR function and the complexity of the relationships between FcgammaRs and antibodies is fuelling efforts to develop more potent \"next-gen\" therapeutic antibodies. Such development strategies now include focused glycan or protein engineering of the Fc to increase affinity and/or tailor specificity for selective engagement of individual activating FcgammaRs or the inhibitory FcgammaRIIb or alternatively, for the ablation of FcgammaR interaction altogether. This review touches on recent aspects FcgammaR and IgG immunobiology and its relationship to the present and future actions of therapeutic mAbs."],"journal":"Immunol Cell Biol","authors":["Chenoweth, Alicia M","Wines, Bruce D","Anania, Jessica C","Mark Hogarth, P"],"date":"2020-03-12T11:00:00Z","year":2020,"_id":"32157732","week":"202011|Mar 09 - Mar 15","doi":"10.1111/imcb.12326","keywords":["ADCC","ADCP","Antibodies; Coronavirus","Fc Receptors","SARS-CoV-2","biologic drugs","immune agonism","monoclonal antibodies","phagocytosis","translational immunology"],"source":"PubMed","topics":["Treatment"],"weight":1,"e_drugs":["Polysaccharides"],"_version_":1663352134073057280,"score":65.183876},{"pmid":32275855,"title":"Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2.","text":["Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2.","The recent emergence of a novel coronavirus (SARS-CoV-2) in China has caused significant public health concerns. Recently, ACE2 was reported as an entry receptor for SARS-CoV-2. In this study, we present the crystal structure of the C-terminal domain of SARS-CoV-2 (SARS-CoV-2-CTD) spike (S) protein in complex with human ACE2 (hACE2), which reveals a hACE2-binding mode similar overall to that observed for SARS-CoV. However, atomic details at the binding interface demonstrate that key residue substitutions in SARS-CoV-2-CTD slightly strengthen the interaction and lead to higher affinity for receptor binding than SARS-RBD. Additionally, a panel of murine monoclonal antibodies (mAbs) and polyclonal antibodies (pAbs) against SARS-CoV-S1/receptor-binding domain (RBD) were unable to interact with the SARS-CoV-2 S protein, indicating notable differences in antigenicity between SARS-CoV and SARS-CoV-2. These findings shed light on the viral pathogenesis and provide important structural information regarding development of therapeutic countermeasures against the emerging virus.","Cell","Wang, Qihui","Zhang, Yanfang","Wu, Lili","Niu, Sheng","Song, Chunli","Zhang, Zengyuan","Lu, Guangwen","Qiao, Chengpeng","Hu, Yu","Yuen, Kwok-Yung","Wang, Qisheng","Zhou, Huan","Yan, Jinghua","Qi, Jianxun","32275855"],"abstract":["The recent emergence of a novel coronavirus (SARS-CoV-2) in China has caused significant public health concerns. Recently, ACE2 was reported as an entry receptor for SARS-CoV-2. In this study, we present the crystal structure of the C-terminal domain of SARS-CoV-2 (SARS-CoV-2-CTD) spike (S) protein in complex with human ACE2 (hACE2), which reveals a hACE2-binding mode similar overall to that observed for SARS-CoV. However, atomic details at the binding interface demonstrate that key residue substitutions in SARS-CoV-2-CTD slightly strengthen the interaction and lead to higher affinity for receptor binding than SARS-RBD. Additionally, a panel of murine monoclonal antibodies (mAbs) and polyclonal antibodies (pAbs) against SARS-CoV-S1/receptor-binding domain (RBD) were unable to interact with the SARS-CoV-2 S protein, indicating notable differences in antigenicity between SARS-CoV and SARS-CoV-2. These findings shed light on the viral pathogenesis and provide important structural information regarding development of therapeutic countermeasures against the emerging virus."],"journal":"Cell","authors":["Wang, Qihui","Zhang, Yanfang","Wu, Lili","Niu, Sheng","Song, Chunli","Zhang, Zengyuan","Lu, Guangwen","Qiao, Chengpeng","Hu, Yu","Yuen, Kwok-Yung","Wang, Qisheng","Zhou, Huan","Yan, Jinghua","Qi, Jianxun"],"date":"2020-04-11T11:00:00Z","year":2020,"_id":"32275855","week":"202015|Apr 06 - Apr 12","doi":"10.1016/j.cell.2020.03.045","keywords":["ACE2","CTD","SARS-CoV-2","crystal structure","immunogenicity","receptor","receptor binding domain"],"source":"PubMed","locations":["China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Mechanism","Treatment"],"weight":1,"_version_":1663712077925056512,"score":54.547813},{"pmid":32203188,"title":"Functional exhaustion of antiviral lymphocytes in COVID-19 patients.","text":["Functional exhaustion of antiviral lymphocytes in COVID-19 patients.","Cell Mol Immunol","Zheng, Meijuan","Gao, Yong","Wang, Gang","Song, Guobin","Liu, Siyu","Sun, Dandan","Xu, Yuanhong","Tian, Zhigang","32203188"],"journal":"Cell Mol Immunol","authors":["Zheng, Meijuan","Gao, Yong","Wang, Gang","Song, Guobin","Liu, Siyu","Sun, Dandan","Xu, Yuanhong","Tian, Zhigang"],"date":"2020-03-24T11:00:00Z","year":2020,"_id":"32203188","week":"202013|Mar 23 - Mar 29","doi":"10.1038/s41423-020-0402-2","source":"PubMed","topics":["Treatment"],"weight":1,"_version_":1663352133658869761,"score":42.37659},{"pmid":32220710,"pmcid":"PMC7118521","title":"Renin-angiotensin system: The unexpected flaw inside the human immune system revealed by SARS-CoV-2.","text":["Renin-angiotensin system: The unexpected flaw inside the human immune system revealed by SARS-CoV-2.","Med Hypotheses","Roncati, Luca","Gallo, Graziana","Manenti, Antonio","Palmieri, Beniamino","32220710"],"journal":"Med Hypotheses","authors":["Roncati, Luca","Gallo, Graziana","Manenti, Antonio","Palmieri, Beniamino"],"date":"2020-03-30T11:00:00Z","year":2020,"_id":"32220710","week":"202014|Mar 30 - Apr 05","doi":"10.1016/j.mehy.2020.109686","source":"PubMed","topics":["Mechanism","Treatment"],"weight":1,"_version_":1663352135177207808,"score":42.27529},{"pmid":32209889,"title":"Advances in the relationship between coronavirus infection and coagulation function.","text":["Advances in the relationship between coronavirus infection and coagulation function.","Chin Med J (Engl)","Zou, Hai","Xiong, Wan-Feng","32209889"],"journal":"Chin Med J (Engl)","authors":["Zou, Hai","Xiong, Wan-Feng"],"date":"2020-03-27T11:00:00Z","year":2020,"_id":"32209889","week":"202013|Mar 23 - Mar 29","doi":"10.1097/CM9.0000000000000821","source":"PubMed","topics":["Mechanism","Treatment"],"weight":1,"_version_":1663352134939181056,"score":41.979317}]}